3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
10
Carcinoma, Non-Small-Cell Lung
9
Triple Negative Breast Neoplasms
8
Breast Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Neoplasms
5
Neoplasm Metastasis
4
Lung Neoplasms
4
Adenocarcinoma
3
Stomach Neoplasms
2
Pancreatic Diseases
2
Neoplasms by Site
2
Endocrine System Diseases
2
Endocrine Gland Neoplasms
2
Digestive System Neoplasms
2
Digestive System Diseases
2
Carcinoma, Pancreatic Ductal
2
Carcinoma, Ductal, Breast
2
Carcinoma
2
Uterine Cervical Neoplasms
1
Squamous Cell Non-small Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Radiation Injuries
1
Pericardial Effusion
1
Pancreatic Cancer Non-resectable
1
Pancreatic Adenocarcinoma
1
Non-Small-Cell Lung
1
Non Small Cell Lung Cancer NSCLC
1
Neuralgia
1
Neoplasms, Unknown Primary
1
Interventions
tremelimumab
1
durvalumab
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Non Small Cell Lung Cancer NSCLC
×
Albumin-Bound Paclitaxel
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA